At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, discusses the anti-CD38 monoclonal antibody, daratumumab, for the treatment of patients with pretreated multiple myeloma.
Daratumumab for heavily pretreated multiple myeloma
26th August 2015
Oncology
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now